Dyne clos­es $345M pub­lic of­fer­ing a week af­ter ear­ly pos­i­tive da­ta for dy­s­tro­phy drugs

Dyne Ther­a­peu­tics com­plet­ed its pub­lic of­fer­ing on Thurs­day af­ter pre­sent­ing ini­tial da­ta from Phase I/II dy­s­tro­phy tri­als study­ing two trans­fer­rin re­cep­tor-tar­get­ing drug can­di­dates.

The Waltham …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER